Table 4.
Treatment | PFS | p value | OS | p value |
---|---|---|---|---|
AVOREN Study | ||||
Interferon-α + bevacizumab | 10.2 | 0.0001 | NR | NA |
Interferon-α | 5.4 | 19.8 | ||
CALGB 90206 | ||||
Interferon-α + bevacizumab | 8.5 | 0.0001 | NR | NA |
Interferon-α | 5.2 | NR |
NR, not reached; OS, overall survival; PFS, progression-free survival.